Program Goals
description
Transcript of Program Goals
![Page 1: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/1.jpg)
Pioneering the Future: Innovations and Strategies for Preventing
Chemotherapy-Induced Nausea and Vomiting
![Page 2: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/2.jpg)
Program Goals
![Page 3: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/3.jpg)
The Importance of Controlling Nausea and Vomiting in the Setting
of Chemotherapy
![Page 4: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/4.jpg)
CINV: Consequences
![Page 5: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/5.jpg)
Emetogenicity of IV Chemotherapy
![Page 6: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/6.jpg)
Emetogenicity of Oral Chemotherapy
![Page 7: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/7.jpg)
Types of CINV
![Page 8: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/8.jpg)
Neurotransmitters Involved in Emesis
![Page 9: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/9.jpg)
Major Classes of Antiemetic Agents: Definitions
![Page 10: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/10.jpg)
Pharmacokinetic and Physiological Differences Among 5-HT3 RAs
![Page 11: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/11.jpg)
CINV Clinical Practice GuidelinesRecommendations and Related Evidence
![Page 12: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/12.jpg)
HEC: Guideline Recommendations
![Page 13: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/13.jpg)
![Page 14: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/14.jpg)
Olanzapine + PALO + DEX vs APR + PALO + DEX: Efficacy
![Page 15: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/15.jpg)
Olanzapine + PALO + DEX vs APR + PALO + DEX: Safety
![Page 16: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/16.jpg)
MEC: Guideline Recommendations
![Page 17: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/17.jpg)
PALO + DEX vs GRN + DEX in Chemotherapy-Naive Patients Receiving Cisplatin (≥ 50 mg/m2)
or AC-Based Chemotherapy
![Page 18: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/18.jpg)
Gaps/Goals: MEC and HEC Settings
![Page 19: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/19.jpg)
Should DEX be Administered on Days 1-3 or Day 1 Only When Given
in Combination With PALO?
![Page 20: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/20.jpg)
Assessing the Efficacy of Single-dose DEX in Chemotherapy-Naive
Patients Receiving AC-Based Chemotherapy
![Page 21: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/21.jpg)
![Page 22: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/22.jpg)
Steroid Sparing in Non-AC MEC: Efficacy
![Page 23: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/23.jpg)
Steroid Sparing in Non-AC MEC: Treatment-Related AEs
![Page 24: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/24.jpg)
Emerging Treatments for Preventing CINV
![Page 25: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/25.jpg)
5-HT3 RAs
![Page 26: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/26.jpg)
NK-1 RAs: Available Formulations
![Page 27: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/27.jpg)
Investigational NK-1 RAs
![Page 28: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/28.jpg)
Phase 2 Trial: Rolapitant (200 mg oral) + OND + DEX in
Chemotherapy-Naive Patients Receiving HEC
![Page 29: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/29.jpg)
Oral NEPA + Oral DEX vs Oral PALO + Oral DEX in AC-Based MEC: Multinational, Randomized,
Double-Blind Phase 3 Study
![Page 30: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/30.jpg)
NEPA + DEX vs PALO + DEX in AC-Based MEC: Efficacy Outcomes
![Page 31: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/31.jpg)
NEPA + DEX vs PALO + DEX in AC-Based MEC: Safety
![Page 32: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/32.jpg)
NEPA: Phase 2 Netupitant Dose-Finding Study
Study Design
![Page 33: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/33.jpg)
NEPA: Phase 2 Netupitant Dose-Finding StudyOverall CR Rates
![Page 34: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/34.jpg)
NEPA: Phase 2 TrialSecondary Efficacy Endpoints
![Page 35: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/35.jpg)
NEPA in Multicycle MEC and HEC: Multicenter, Randomized, Double-
blind, Phase 3 Study
![Page 36: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/36.jpg)
NEPA in Multicycle MEC and HEC: Overall CR Rates
![Page 37: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/37.jpg)
NEPA in Multicycle MEC and HEC: Most Common AEs
![Page 38: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/38.jpg)
Innovations and Strategies in the Prevention of CINV: Summary
![Page 39: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/39.jpg)
Abbreviations
![Page 40: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/40.jpg)
Abbreviations (cont)
![Page 41: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/41.jpg)
References
![Page 42: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/42.jpg)
References (cont)
![Page 43: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/43.jpg)
References (cont)
![Page 44: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/44.jpg)
References (cont)
![Page 45: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/45.jpg)
References (cont)
![Page 46: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/46.jpg)
References (cont)
![Page 47: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/47.jpg)
References (cont)
![Page 48: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/48.jpg)
References (cont)
![Page 49: Program Goals](https://reader036.fdocuments.in/reader036/viewer/2022062520/5681614e550346895dd0d361/html5/thumbnails/49.jpg)
References (cont)